Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | AG-270 + Docetaxel |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AG-270 | AG270|AG 270 | AG-270 inhibits methionine adenosyltransferase II alpha (MAT2A), to induce cell death of tumor cells reliant on S-Adenosyl-L-methionine (SAM) synthesis (NCI Drug Dictionary). | ||
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Terminated | USA | FRA | ESP | 0 |